Vertex Pharmaceuticals Incorporated

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 07/07/2025 BST			5-day change	1st Jan Change
459.41 ^USD	-0.05%		+3.19%	+14.08%

07-07	RBC Raises Price Target on Vertex Pharmaceuticals to $430 From $420, Keeps Sector Perform Rating	MT
07-03	Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials	MT

Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550

Published on 23/05/2025 at 13:09

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vertex Pharmaceuticals Incorporated

RBC Raises Price Target on Vertex Pharmaceuticals to $430 From $420, Keeps Sector Perform Rating	07-07	MT
Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials	07-03	MT
Vertex Pharmaceuticals Presents Longer-Term Data at the 2025 European Hematology Association Congress Demonstrating Durability of CASGEVY®? and Provides Update on Expanding Global Access to CASGEVY	07-03	CI
Vertex Pharmaceuticals Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis	07-01	CI
EU approves Vertex's next-generation cystic fibrosis drug	07-01	RE
EU approves Vertex's next-generation cystic fibrosis drug	07-01	RE
Vertex Pharmaceuticals Says European Commission Approves Alyftrek for Treating Cystic Fibrosis	07-01	MT
Vertex's next-generation cystic fibrosis drug gets EU approval	07-01	RE
Vertex Pharmaceuticals Incorporated Presents at American Diabetes Association 85th Scientific Sessions, Jun-20-2025 07:15 PM	06-30
AbbVie to buy Capstan for up to $2.1 billion in immunology push	06-30	RE
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Dynamic Index	06-30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Value-Defensive Index	06-30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Value Index	06-30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000 Value Index	06-30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Value Index	06-30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Value Index	06-30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Value Benchmark	06-29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Value Benchmark	06-29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000 Value Benchmark	06-29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Value Benchmark	06-29	CI
Vertex Pharmaceuticals Incorporated and Ono Pharmaceutical Co., Ltd. Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea	06-23	CI
Vertex Pharmaceuticals, Ono Sign License Deal for Povetacicept in Japan, South Korea	06-23	MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $460 From $464	06-20	MT
RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating	06-17	MT
Saudi Arabia Signs Multiple Healthcare Deals, Partnerships at BIO 2025	06-17	MT

Chart Vertex Pharmaceuticals Incorporated

Duration

Period

Chart Vertex Pharmaceuticals Incorporated

VRTX: Dynamic Chart

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (60.7%), Europe (31.3%) and other (8%).

Employees

6,100

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company